Breast Cancer
First- vs. second-line CDK4/6 inhibitor use fails to benefit breast cancer subgroup
CHICAGO — First-line use of cyclin-dependent kinase 4/6 inhibitors did not confer significant benefit vs. second-line use when added to endocrine therapy for women with hormone receptor-positive, HER2-negative, advanced breast cancer.
Sacituzumab govitecan shows ‘enduring benefits’ in metastatic breast cancer subset
CHICAGO — Sacituzumab govitecan continued to show significant improvement in OS among patients with heavily pretreated metastatic hormone receptor-positive breast cancer, according to final OS results of the phase 3 TROPiCS-02 study.
Top in women’s health: Breast density guidance; drug implant for bothersome bleeding
In March, the FDA updated mammography regulations to include a lay language summary for patients on breast density reporting.
Trastuzumab deruxtecan shows ‘broad activity’ in HER2-expressing solid tumors
CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.
Strategy may enable some patients with HER2-positive breast cancer to avoid chemotherapy
CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.
Toripalimab regimen delays progression of PD-L1-positive triple-negative breast cancer
CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.
Long-duration trastuzumab remains standard of care in HER2-positive breast cancer
CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.
Ribociclib regimen reduces recurrence risk in common breast cancer subtype
CHICAGO — The addition of ribociclib to endocrine therapy improved invasive DFS vs. endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.
Breast density reporting requirements change, clinical guidance remains unchanged
BALTIMORE — A late-breaking session at the ACOG Annual Clinical & Scientific Meeting highlighted FDA updates in breast density reporting that include a lay summarization for patients while ACOG clinical guidance on breast density remains unchanged.
Telephone-based intervention helps women with breast cancer lose weight
Women with breast cancer whose BMI fell in the overweight or obese ranges achieved meaningful weight loss via a telephone-based intervention, according to phase 3 study results.